RxDoctor Payments Data

Danielle Steffan

Physician Assistant · Cambridge, MDNPI 1568061794

Payments from drug & device makers

$6,929in general payments, 2019–2025

Across 288 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • Johnson & Johnson$657
  • UCB, Inc.$538
  • AstraZeneca$525
  • Mallinckrodt Hospital Products Inc.$404
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,42293%
  • Education$5077%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,929 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$2,908
Medicare patients
24
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab51$399,866
RinvoqUpadacitinib25$212,046
Enbrel SureclickEtanercept19$151,024
Xeljanz XrTofacitinib Citrate23$147,569
RemicadeInfliximab18$99,409
ActemraTocilizumab15$72,938
Actemra ActpenTocilizumab18$61,232
ProliaDenosumab22$39,241
Hydroxychloroquine Sulfate286$14,236
MethotrexateMethotrexate Sodium215$6,481
Celecoxib101$3,694
Prednisone302$2,284
Alendronate Sodium256$2,080
Gabapentin168$2,001
Duloxetine Hcl54$1,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,328$212,04625 claims
Johnson & JohnsonRemicade$657$99,40918 claims
AmgenProlia$1,389$39,24122 claims
Fresenius Kabi USA, LLCSodium Chloride$116$9023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Cambridge

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →